CAS No.: 247062-33-5
Molecular Weight: 3960.657 g/mol
Impurity ≤0.5% ;
Storage Temperature 2-8℃;
Packing Size 1G/Bottle, 10G/Bottle,50G/Bottle or at customers reqirement.
Abaloparatide is an analog of PTHrP (parathyroid hormone-related protein). It was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a synthetic peptide that is related to hPTHrP and has demonstrated in preclinical testing the potential to widen the anabolic window for bone therapeutics, stimulating bone formation with a limited effect on bone resorption and mineral mobilization. This could enable improved convenience over currently available anabolic therapies, resulting in greater compliance and, ultimately, greater benefit to patients.
Main Information: In 28 April 2017, it was approved by Food and drug administration to treat postmenopausal osteoporosis. Abaloparatide is a parathyroid hormone-related protein (PTHrP) analog drug used to treat osteoporosis. Like the related drug teriparatide, and unlike bisphosphonates, it is an anabolic (i.e., bone growing) agent. A subcutaneous injection formulation of the drug has completed a Phase III trial for osteoporosis. This single study found a decrease in fractures. A transdermal patch is also in development.